Literature DB >> 26529299

Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.

Irina Tretyakova1, Rachmat Hidajat1, Garrett Hamilton1, Noah Horn1, Brian Nickols1, Raphael O Prather1, Terrence M Tumpey2, Peter Pushko3.   

Abstract

Influenza VLPs comprised of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins have been previously used for immunological and virological studies. Here we demonstrated that influenza VLPs can be made in Sf9 cells by using the bovine immunodeficiency virus gag (Bgag) protein in place of M1. We showed that Bgag can be used to prepare VLPs for several influenza subtypes including H1N1 and H10N8. Furthermore, by using Bgag, we prepared quadri-subtype VLPs, which co-expressed within the VLP the four HA subtypes derived from avian-origin H5N1, H7N9, H9N2 and H10N8 viruses. VLPs showed hemagglutination and neuraminidase activities and reacted with specific antisera. The content and co-localization of each HA subtype within the quadri-subtype VLP were evaluated. Electron microscopy showed that Bgag-based VLPs resembled influenza virions with the diameter of 150-200nm. This is the first report of quadri-subtype design for influenza VLP and the use of Bgag for influenza VLP preparation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Avian influenza; BIV gag; H10N8; H5N1; H7N9; H9N2; VLP vaccine; Virus-like particle

Mesh:

Substances:

Year:  2015        PMID: 26529299      PMCID: PMC4679414          DOI: 10.1016/j.virol.2015.10.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  58 in total

1.  Isolation and characteristic analysis of a novel strain H7N9 of avian influenza virus A from a patient with influenza-like symptoms in China.

Authors:  Faming Chen; Junhua Li; Biancheng Sun; Hong Zhang; Rusheng Zhang; Jie Yuan; Xinhua Ou; Wen Ye; Jingfang Chen; Yunzhi Liu; Yiwei Huang
Journal:  Int J Infect Dis       Date:  2015-01-19       Impact factor: 3.623

Review 2.  Vaccines against influenza A viruses in poultry and swine: Status and future developments.

Authors:  J Rahn; D Hoffmann; T C Harder; M Beer
Journal:  Vaccine       Date:  2015-03-31       Impact factor: 3.641

3.  Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.

Authors:  Peter Pushko; Terrence M Tumpey; Neal Van Hoeven; Jessica A Belser; Robin Robinson; Margret Nathan; Gale Smith; D Craig Wright; Rick A Bright
Journal:  Vaccine       Date:  2007-03-09       Impact factor: 3.641

Review 4.  Toward a universal influenza virus vaccine: prospects and challenges.

Authors:  Natalie Pica; Peter Palese
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

Review 5.  Influenza: old and new threats.

Authors:  Peter Palese
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

6.  Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.

Authors:  Fu-Shi Quan; Aswani Vunnava; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

7.  Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains.

Authors:  Jorge C G Blanco; Lioubov M Pletneva; Hongquan Wan; Yonas Araya; Matthew Angel; Raymonde O Oue; Troy C Sutton; Daniel R Perez
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

Review 8.  Making better influenza virus vaccines?

Authors:  Peter Palese
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

9.  Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers.

Authors:  F Boulay; R W Doms; R G Webster; A Helenius
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539

10.  Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Sang-Moo Kang
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more
  12 in total

1.  Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.

Authors:  Peter Pushko; Irina Tretyakova; Rachmat Hidajat; Xiangjie Sun; Jessica A Belser; Terrence M Tumpey
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

Review 2.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

3.  Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.

Authors:  Peter Pushko; Irina Tretyakova; Rachmat Hidajat; Aniko Zsak; Klaudia Chrzastek; Terrence M Tumpey; Darrell R Kapczynski
Journal:  Virology       Date:  2016-12-06       Impact factor: 3.616

4.  Intensifying Continuous Production of Gag-HA VLPs at High Cell Density Using Stable Insect Cells Adapted to Low Culture Temperature.

Authors:  Bárbara Fernandes; Ricardo Correia; Paula M Alves; António Roldão
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

5.  Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.

Authors:  Peter Pushko; Xiangjie Sun; Irina Tretyakova; Rachmat Hidajat; Joanna A Pulit-Penaloza; Jessica A Belser; Taronna R Maines; Terrence M Tumpey
Journal:  Vaccine       Date:  2016-09-20       Impact factor: 3.641

6.  Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization.

Authors:  Dustin M McCraw; John R Gallagher; Udana Torian; Mallory L Myers; Michael T Conlon; Neetu M Gulati; Audray K Harris
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

7.  Bioanalytics for Influenza Virus-Like Particle Characterization and Process Monitoring.

Authors:  Sofia B Carvalho; Ricardo J S Silva; Marcos F Q Sousa; Cristina Peixoto; António Roldão; Manuel J T Carrondo; Paula M Alves
Journal:  Front Bioeng Biotechnol       Date:  2022-02-18

Review 8.  Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.

Authors:  Peter Pushko; Irina Tretyakova
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

Review 9.  Synthetic biology for bioengineering virus-like particle vaccines.

Authors:  Hayley K Charlton Hume; João Vidigal; Manuel J T Carrondo; Anton P J Middelberg; António Roldão; Linda H L Lua
Journal:  Biotechnol Bioeng       Date:  2018-12-31       Impact factor: 4.530

10.  Progress in the development of virus-like particle vaccines against respiratory viruses.

Authors:  Fu-Shi Quan; Swarnendu Basak; Ki-Back Chu; Sung Soo Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2020-01-18       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.